Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Tongji Hospital
Tianjin Medical University Cancer Institute and Hospital
Asan Medical Center
Asan Medical Center
Tianjin Medical University Cancer Institute and Hospital
OHSU Knight Cancer Institute
University of Hawaii
University Hospital, Angers
Asan Medical Center
Virginia Commonwealth University
CHA University
Zhejiang University
First Hospital of China Medical University
Lepu Biopharma Co., Ltd.
Nanfang Hospital, Southern Medical University
Tianjin Medical University Cancer Institute and Hospital
AstraZeneca
Post Graduate Institute of Medical Education and Research, Chandigarh
First Affiliated Hospital of Wenzhou Medical University
West China Hospital
University of Geneva, Switzerland
University of Texas Southwestern Medical Center
Second Affiliated Hospital, School of Medicine, Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Fudan University
OHSU Knight Cancer Institute
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Sun Yat-sen University
Philips Clinical & Medical Affairs Global
University of California, San Francisco
Henan Cancer Hospital
Rigshospitalet, Denmark
Eunice Dube
Changchun GeneScience Pharmaceutical Co., Ltd.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eastern Hepatobiliary Surgery Hospital
First Affiliated Hospital of Chongqing Medical University
Shanghai Zhongshan Hospital
Fujian Cancer Hospital
Siriraj Hospital
Fudan University
Third Affiliated Hospital, Sun Yat-Sen University
Hebei Medical University Fourth Hospital
AccSalus Biosciences, Inc.
Sun Yat-sen University
Twinpig Biolab, Inc.
University of Texas Southwestern Medical Center
Broadenbio Ltd., Co.
Medical University of Warsaw